Introduction {#s1}
============

Vitamin D deficiency is observed in the vast majority of haemodialysis patients, and there is accumulating evidence that vitamin D, beyond its effects on bone and mineral metabolism, is also crucial for cardiovascular health and protection against infectious diseases.^[@EHQ246C1]--[@EHQ246C9]^ In general, vitamin D from either ultraviolet B-induced synthesis in the skin or from nutritional intake is hydroxylated to 25-hydroxyvitamin D \[25(OH)D\] in the liver. 25(OH)D circulates in up to 1000-fold higher concentrations than the most potent vitamin D metabolite 1,25-dihydroxyvitamin D \[1,25(OH)2D, calcitriol\].^[@EHQ246C8],[@EHQ246C9]^ The renal production of 1,25(OH)2D is tightly controlled by homoeostatic mechanisms but becomes significantly dependent on substrate availability when circulating 25(OH)D are low.^[@EHQ246C8]^ In addition, various extrarenal tissues including the myocardium and vasculature have been shown to express 1α-hydroxylase and are thus capable of producing large amounts of 1,25(OH)2D.^[@EHQ246C8],[@EHQ246C9]^ Of note, locally produced 1,25(OH)2D, the synthesis of which is dependent on circulating 25(OH)D levels, exerts its effects predominantly in an autocrine and paracrine manner thereby regulating approximately 3% of the human genome.^[@EHQ246C8]--[@EHQ246C10]^

In patients with chronic kidney disease (CKD), limited sunlight exposure and reduced capacity of the skin to synthesize vitamin D as well as loss of vitamin D-binding protein in the urine are mainly responsible for the high prevalence of depressed 25(OH)D levels, which are used to assess vitamin D status.^[@EHQ246C1]--[@EHQ246C9],[@EHQ246C11]^ Given that the kidney is the main source for circulating 1,25(OH)2D, which is crucial for calcium and phosphorus as well as parathyroid hormone (PTH) homeostasis, 1,25(OH)2D and its analogues are routinely supplemented in many end-stage CKD patients, and this therapy is associated with improved survival.^[@EHQ246C10]^ Besides the use of this therapy with active vitamin D, little attention has been paid in the past to 25(OH)D levels, which can be raised by supplementation with the precursor vitamin D. Recent studies have, however, shown that in CKD low 25(OH)D levels are a significant risk factor for cardiovascular diseases (CVDs) and mortality.^[@EHQ246C1]--[@EHQ246C7]^ In a nested case--control study among 1000 incident haemodialysis patients, there was a significantly increased 90-day mortality in the group with the lowest 25(OH)D levels.^[@EHQ246C4]^ However, data on long-term mortality and specific cardiovascular events (CVE), such as sudden cardiac death (SCD) or stroke, being significantly associated with vitamin D deficiency in patients undergoing coronary angiography,^[@EHQ246C12],[@EHQ246C13]^ are lacking for haemodialysis patients. In view of the particularly high incidence of SCD in dialysis patients, accounting for one-quarter of all deaths, such data are needed to gain a better understanding of the diagnostic and probably therapeutic implications of vitamin D in these patients. Hence, we investigated the effect of 25(OH)D levels on SCD in relation to other cardiac, vascular, and infection-related outcomes in a large well-characterized cohort of haemodialysis patients.^[@EHQ246C14]^

Methods {#s2}
=======

Study design and participants {#s2a}
-----------------------------

The German Diabetes and Dialysis Study (4D study) methodology has previously been reported in detail.^[@EHQ246C14]^ Briefly, the 4D study was a prospective randomized controlled trial (RCT), including 1255 patients with type 2 diabetes mellitus, aged 18--80 years, and on haemodialysis for \<2 years. Between March 1998 and October 2002, patients were recruited in 178 dialysis centres in Germany. After a period of 4 weeks, patients were randomly assigned to double-blinded treatment with either 20 mg of atorvastatin (*n* = 619) or placebo (*n* = 636) once daily. Study visits took place three times before randomization (Visits 1--3), at randomization (Visit 4), and at 4 weeks (Visit 5), and every 6 months (Visit 6) after randomization until the date of death, censoring, or end of the study in March 2004. The primary endpoint of the 4D study was defined as a composite of death from cardiac causes, fatal or non-fatal stroke, and non-fatal myocardial infarction (MI), whichever occurred first (composite cardiovascular endpoint; CVE). Death from cardiac causes comprised SCD, fatal MI, death due to congestive heart failure (CHF), death due to coronary heart disease during or within 28 days after an intervention, and all other deaths ascribed to coronary heart disease. Sudden cardiac death was considered as: death verified by terminal rhythm disorders in an electrocardiogram; by witnesses observed death within 1 h after the onset of cardiac symptoms; confirmed by autopsy; unexpected death, presumably or possibly of cardiac origin and in the absence of a potassium level ≥7.5 mmol/L before the start of the three most recent sessions of haemodialysis. Myocardial infarction was diagnosed when two of the following three criteria were met: typical symptoms, elevated levels of cardiac enzymes (i.e. a level of creatine kinase MB above 5% of the total level of creatine kinase, a level of lactic dehydrogenase 1.5 times the upper limit of normal, or a level of troponin T \>2 ng/mL), or diagnostic changes on the electrocardiogram. German Diabetes and Dialysis Study endpoints were centrally adjudicated by three members of the endpoint committee blinded to study treatment and according to pre-defined criteria.

In the present analysis, SCD, MI (fatal and non-fatal), stroke (fatal and non-fatal), the primary endpoint (CVE), death due to CHF, death due to infection, and all-cause mortality were all chosen to be separate outcome measures. The study complies with the Declaration of Helsinki, was approved by the medical Ethics Committee, and all patients gave their written informed consent before inclusion.

Data collection {#s2b}
---------------

Information on age, gender, and smoking status was obtained through patient interviews. Smoking status was classified as never, former, or current. Comorbidities, including the presence of coronary artery disease (CAD) and CHF, as well as the duration of diabetes mellitus and dialysis treatment were reported by the patients\' nephrologists. Coronary artery disease was defined by the history of MI, coronary artery bypass grafting surgery, percutaneous coronary intervention, and the presence of coronary heart disease, as documented by coronary angiography. Left ventricular hypertrophy (LVH) was based on ECG criteria. Blood pressure was measured in sitting position. Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared. Levels of 25(OH)D were measured in serum samples taken at baseline at study Visit 3 (1 week before randomization) and stored without repeated freeze thaw cycles at −80°C until measurement in November 2009. Determinations in serum were performed by means of a chemiluminescence assay (IDS, iSYS 25(OH)D; Immunodiagnostic systems Ltd, Boldon, UK) on an IDS-iSYS multi-discipline automated analyser. Within-day coefficients of variation (CV) were 5.5--12.1% and inter-day CV were 8.9--16.9%, respectively. All blood samples were taken before the start of dialysis sessions and administration of drugs.

Statistical analysis {#s2c}
--------------------

Continuous variables were expressed as mean with standard deviation or median with interquartile range as appropriate, and categorical variables were expressed as percentages.

The study population was divided into four groups according to their 25(OH)D status at baseline. In line with widely used cut-off values, patients were grouped into severely vitamin D deficient (≤25 nmol/L), moderately vitamin D deficient (\>25 and ≤50 nmol/L), vitamin D insufficient (\>50 and ≤75 nmol/L), and vitamin D sufficient (\>75 nmol/L, to convert nanomolar to nanogram per millilitre divide by 2.496).^[@EHQ246C4],[@EHQ246C8],[@EHQ246C12]^ For comparisons across baseline vitamin D groups, we used ANOVA and *χ*^2^ test, as appropriate. In our prospective analyses, we assessed the association of baseline 25(OH)D with SCD, both as continuous and as categorical variable. For the latter, the patients with sufficient 25(OH)D levels were used as the reference group. Absolute (incidence) rates were calculated, and the relative risks derived from Cox regression analyses, i.e. hazard ratios (HR) and corresponding 95% confidence intervals (CI). The Cox regression analyses were adjusted for the confounders age, sex, atorvastatin treatment, use of angiotensin-converting enzyme inhibitors, beta-blockers, and diuretics, CAD, CHF, systolic blood pressure, smoking status, duration of dialysis, ultrafiltration volume, BMI, levels of low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, C-reactive protein, and glycohaemoglobin A1c. To account for the seasonal variation of 25(OH)D, we furthermore adjusted our analyses for the season of blood draw. We, therefore, used a binary variable reflecting the months October to March and April to September. Second, to explore the possible pathways, we performed additional analyses with inclusion of potential intermediate conditions including levels of calcium, PTH, and phosphate. The use of active vitamin D treatment was, furthermore, considered in additional multivariate analyses. Third, we investigated 25(OH)D and the risk of other adverse cardiac and vascular outcomes including MI, stroke, the combined primary endpoint, and death due to CHF. Furthermore, we evaluated the association of 25(OH)D levels with all-cause mortality and fatal infections. In addition, we used an alternative approach to account for the seasonal fluctuation of 25(OH)D and calculated *z*-values of logarithmically transformed 25(OH)D levels based on their means and standard deviation values within each month of blood sampling (formula for *z*-values: X-mean/standard deviation). Finally, we tested for interactions of statin use (yes/no), active vitamin D treatment (yes/no), prior CVD (yes/no), and event rates in our prospective analyses by adding product terms to our Cox proportional hazards models.

All *P*-values are reported two-sided, and a *P*-value \<0.05 was considered statistically significant. Analyses were performed using SPSS version 16.0.

Results {#s3}
=======

Patient characteristics {#s3a}
-----------------------

Between March 1998 and October 2002, a total of 1255 patients were included into the 4D study, of whom 1108 had a measurement of 25(OH)D at baseline. The mean follow-up period was 3.96 years (median 4.0 years) on atorvastatin and 3.91 years (median 4.08 years) on placebo. During follow-up, 414 of the 1108 patients reached the primary endpoint of CVE. In our primary analyses, there was no significant effect of atorvastatin treatment on CVE.^[@EHQ246C14]^ A total of 545 patients died, of whom 146 patients died of SCD. Furthermore, 37 patients died due to CHF, and 111 patients died due to infection. A total of 174 patients experienced an MI (fatal or non-fatal) and 89 patients experienced a stroke (fatal or non-fatal).

In the study population (*n* = 1108), the mean (standard deviation) age was 66 (8) years and 54% of the patients were male. In general, the median (interquartile) level of 25(OH)D at baseline was 39 nmol/L (28--55). As expected, we observed a seasonal variation of 25(OH)D in our patients, with the lowest median concentrations of 31 nmol/L in February and the highest median concentrations of 50 nmol/L in August. The patient characteristics are shown in *Table [1](#EHQ246TB1){ref-type="table"}*. Patients with severe vitamin D deficiency were more likely to be female and had higher levels of glycohaemoglobin A1~c~. Furthermore, the burden of LVH was higher, as were the levels of LDL-cholesterol and N-terminal-pro-B-type natriuretic peptide in patients with severe vitamin D deficiency compared with patients with sufficient 25(OH)D levels. Table 1Baseline patient characteristics, presented per vitamin D category; study population (*n* = 1108)CharacteristicVitamin D category \[25(OH)D levels in nmol/L\]*P*-value≤25 (*n*= 177)\>25 and ≤50 (*n* = 607)\>50 and ≤75 (*n* = 210)\>75 (*n* = 114)Age (years)66 (8)66 (8)65 (8)65 (8)0.395Gender (%, (men)49.249.166.267.5\<0.00125(OH)D (nmol/L)20 (17--23)35 (30--42)61 (56--67)94 (83--104)\<0.001Atorvastatin treatment (%)52.049.849.049.10.940Use of active vitamin D (%)22.616.821.014.90.175Systolic BP (mmHg)146 (22)146 (23)144 (20)147 (22)0.772Diastolic BP (mmHg)76 (11)76 (11)76 (11)77 (10)0.495BMI (kg/m^2^)27.4 (5.3)27.7 (4.7)27.5 (4.6)27.0 (4.1)0.505Duration of diabetes (years)19.9 (13.5--25.7)18.0 (11.4--23.8)16.3 (10.0--23.2)18.3 (9.9--22.5)0.003Time on dialysis (months)5.7 (3.2--12.1)6.0 (2.9--11.3)5.8 (3.1--11.7)7.3 (3.9--12.1)0.336Ultrafiltration volume (kg)2.0 (1.2--3.0)2.0 (1.1--3.0)2.0 (2.0--3.0)2.0 (1.0--3.0)0.420Smoker/ex-smoker (%)42.937.843.344.70.247History of CAD (%)28.827.332.436.80.159 CHF (%)37.935.931.040.40.320Presence of LVH (%)14.111.711.412.40.832NYHA class I (%)66.172.076.161.40.039NYHA class II (%)27.723.417.631.6NYHA class III (%)6.24.65.77.0NYHA class IV (%)0.00.00.50.0Beta-blockers (%)26.035.344.348.2\<0.001ACE inhibitors (%)41.845.852.457.00.027Diuretics (%)80.881.277.675.40.418Laboratory parameters LDL-cholesterol (mg/dL)128 (111--145)122 (104--145)121 (103--141)118 (101--142)0.023 HDL-cholesterol (mg/dL)35 (28--44)33 (27--42)33 (26--42)36 (30--44)0.083 Triglycerides (mg/dL)244 (165--322)225 (148--325)222 (160--328)185 (135--302)0.110 Haemoglobin (g/dL)11.0 (1.4)10.9 (1.4)11.0 (1.3)10.9 (1.2)0.533 Albumin (g/dL)3.8 (0.3)3.8 (0.3)3.8 (0.3)3.9 (0.3)0.063 C-reactive protein (mg/L)4.9 (2.5--10.9)5.2 (2.5--13.3)5.3 (2.4--14.2)4.5 (2.1--10.3)0.489 HbA1c (%)6.8 (1.3)6.8 (1.3)6.6 (1.1)6.5 (1.2)0.051 Calcium (mmol/L)2.3 (0.2)2.3 (0.2)2.3 (0.2)2.3 (0.2)0.161 Phosphate (mmol/L)6.2 (1.5)6.0 (1.6)6.1 (1.6)5.7 (1.6)0.060 NT-pro-BNP (pg/mL)3690 (1479--8080)3523 (1524--10 396)3036 (1171--7659)2608 (1087--7026)0.010[^2][^3]

Vitamin D status and risk of sudden cardiac death {#s3b}
-------------------------------------------------

Vitamin D status at baseline was strongly associated with the risk of SCD (*Figure [1](#EHQ246F1){ref-type="fig"}A*). By Cox regression analyses, the unadjusted hazard to experience SCD was 3-fold higher in patients with severe vitamin D deficiency as compared with those with sufficient 25(OH)D levels (HR: 2.99, 95% CI: 1.39--6.40, *Table [2](#EHQ246TB2){ref-type="table"}*). This association was virtually unchanged after controlling for potential confounders and seasonal variation of 25(OH)D (HR: 2.95, 95% CI: 1.35--6.46). Additional adjustment for markers of mineral metabolism including PTH, calcium, and phosphate also did not materially change the results (HR: 3.00, 95% CI: 1.36--6.60), which persisted even after further adjustment for the use of active vitamin D treatment (HR: 3.04, 95% CI: 1.38--6.70). When 25(OH)D was analysed as a continuous variable, the hazard to die suddenly increased by 59% per unit decrease in 25(OH)D levels (*Table [3](#EHQ246TB3){ref-type="table"}*). This association persisted in multivariate analyses. To strengthen our results, we performed additional analyses using *z*-values as an alternative approach to account for the seasonal variation of 25(OH)D. The results were similar, confirming a strong association of low 25(OH)D levels with the risk of SCD (data not shown). Table 2Absolute incidence rates and hazard ratios with 95% confidence intervals (HR, 95% CI) for sudden cardiac death, stroke, myocardial infarction, and death due to heart failure according to levels of 25-hydroxyitamin D at baseline (*n* = 1108)OutcomeVitamin D (nmol/L)≤25 (*n* = 177)\>25 and ≤50 (*n* = 607)\>50 and ≤75 (*n* = 210)\>75 (*n* = 114)Sudden cardiac death Incidence rate/100 persons-years py7.44.53.72.5 Crude HR (95% CI)2.99 (1.39--6.40)1.83 (0.89--3.79)1.49 (0.66--3.35)1 Adjusted^a^ HR (95% CI)2.95 (1.35--6.46)1.71 (0.82--3.60)1.54 (0.68--3.50)1 Adjusted^b^ HR (95% CI)3.00 (1.36--6.60)1.74 (0.83--3.65)1.54 (0.68--3.51)1Stroke Incidence rate/100 py3.82.63.81.2 Crude HR (95% CI)2.97 (1.01--8.75)2.08 (0.75--5.78)3.11 (1.07--9.03)1 Adjusted^a^ HR (95% CI)2.83 (0.82--9.80)1.92 (0.58--6.27)3.53 (1.04--11.92)1 Adjusted^b^ HR (95% CI)2.58 (0.74--8.98)1.79 (0.55--5.90)3.26 (0.96--11.07)1Myocardial infarction Incidence rate/100py persons-years6.75.27.15.2 Crude HR (95% CI)1.29 (0.71--2.34)1.00 (0.59--1.71)1.37 (0.76--2.45)1 Adjusted^a^ HR (95% CI)1.40 (0.76--2.59)1.07 (0.62--1.84)1.44 (0.80--2.60)1 Adjusted^b^ HR (95% CI)1.27 (0.68--2.36)1.01 (0.58--1.74)1.34 (0.74--2.42)1Death due to heart failure Incidence rate/100py persons-years1.61.01.21.2 Crude HR (95% CI)1.27 (0.38--4.23)0.85 (0.29--2.50)0.95 (0.28--3.25)1 Adjusted^a^ HR (95% CI)1.26 (0.36--4.43)0.72 (0.23--2.22)0.89 (0.25--3.12)1 Adjusted^b^ HR (95% CI)0.96 (0.27--3.41)0.61 (0.20--1.90)0.67 (0.19--2.44)1Cardiovascular events Incidence rate/100py persons-years18.213.016.110.2 Crude HR (95% CI)1.78 (1.18--2.69)1.28 (0.88--1.87)1.59 (1.05--2.40)1 Adjusted^a^ HR (95% CI)1.75 (1.14--2.69)1.24 (0.84--1.83)1.65 (1.08--2.51)1 Adjusted^b^ HR (95% CI)1.59 (1.03--2.45)1.18 (0.80--1.75)1.53 (1.01--2.34)1Death due to infection Incidence rate/100py\
persons-years4.33.63.52.2 Crude HR (95% CI)1.92 (0.82--4.51)1.67 (0.76--3.65)1.66 (0.71--3.91)1 Adjusted^a^ HR (95% CI)1.85 (0.77--4.43)1.51 (0.68--3.36)1.61 (0.68--3.84)1 Adjusted^b^ HR (95% CI)1.55 (0.64--3.73)1.35 (0.61--3.02)1.34 (0.56--3.23)1All-cause mortality Incidence rate/100py persons-years22.917.115.113.0 Crude HR (95% CI)1.74 (1.22--2.47)1.32 (0.96--1.83)1.17 (0.81--1.69)1 Adjusted^a^ HR (95% CI)1.79 (1.24--2.59)1.26 (0.90--1.76)1.25 (0.86--1.81)1 Adjusted^b^ HR (95% CI)1.65 (1.14--2.38)1.20 (0.86--1.68)1.16 (0.80--1.70)1[^4][^5] Table 3Risk of cardiovascular events, sudden cardiac death, stroke, myocardial infarction, death due to heart failure, death due to infection, and all-cause mortality per unit decrease in 25-hydroxyvitamin D (continuous variable, log transformed); study population (*n* = 1108)OutcomeHazard ratio (HR) and 95% CICrudeAdjusted^a^Adjusted^b^Sudden cardiac death1.591.551.58(1.14--2.23)(1.08--2.23)(1.09--2.27)*P* = 0.007*P* = 0.017*P* = 0.015Stroke1.451.301.27(0.94--2.23)(0.81--2.07)(0.79--2.03)*P* = 0.09*P* = 0.27*P* = 0.32Myocardial infarction0.991.041.02(0.73--1.35)(0.76--1.44)(0.74--1.40)*P* = 0.96*P* = 0.79*P* = 0.92Death due to heart failure0.960.970.93(0.50--1.85)(0.47--2.00)(0.45--1.92)*P* = 0.90*P* = 0.94*P* = 0.84Cardiovascular events1.181.151.12(0.96--1.43)(0.93--1.42)(0.91--1.38)*P* = 0.11*P* = 0.19*P* = 0.29Death due to infection1.441.461.42(0.98--2.12)(0.96--2.23)(0.93--2.15)*P* = 0.06*P* = 0.07*P* = 0.10All-cause mortality1.381.391.36(1.16--1.64)(1.15--1.68)(1.13--1.64)*P* \< 0.001*P* = 0.001*P* = 0.001[^6][^7] Figure 1Kaplan--Meier curves for the time to (*A*) sudden cardiac death, (*B*) stroke, (*C*) combined cardiovascular events in subgroups of patients according to 25-hydroxyvitamin D levels at baseline \[severely vitamin D deficient (≤25 nmol/L), moderately vitamin D deficient (\>25 and ≤50 nmol/L), vitamin D insufficient (\>50 and ≤75 nmol/L), and vitamin D sufficient (\>75 nmol/L)\].

Vitamin D status and risk of myocardial infarction, stroke, death due to heart failure, and combined cardiovascular events {#s3c}
--------------------------------------------------------------------------------------------------------------------------

There was a trend for higher risks of stroke with lower 25(OH)D levels (*Figure [1](#EHQ246F1){ref-type="fig"}B*). Per unit decrease in 25(OH)D, the risk of stroke increased by 30% after adjustment for confounders. In categorical analyses, patients with severe vitamin D deficiency had a 2.8-fold increased risk of stroke compared with those with normal levels (adjusted HR: 2.83, 95% CI: 0.82--9.80). In contrast, no association of vitamin D status with MI was found. Both in continuous (adjusted HR: 1.04, 95% CI: 0.76--1.44) and in categorical analyses, the risk of MI did not increase at lower levels of 25(OH)D (*Tables [2](#EHQ246TB2){ref-type="table"}* and *[3](#EHQ246TB3){ref-type="table"}*). When non-fatal and fatal MI were analysed separately, the results were similar showing no relation to vitamin D status. The number of deaths due to CHF was small in the present study (*n* = 37). These deaths similarly were not meaningfully affected by vitamin D status.

Finally, the primary endpoint of combined CVE was markedly increased with lower levels of 25(OH)D (*Table [2](#EHQ246TB2){ref-type="table"}* and *Figure [1](#EHQ246F1){ref-type="fig"}C*). Patients with severe vitamin D deficiency had an adjusted 80% higher risk of experiencing a CVE as compared with patients with sufficient vitamin D status (*Table [3](#EHQ246TB3){ref-type="table"}*).

Vitamin D status and risk of death due to infection and all-cause mortality {#s3d}
---------------------------------------------------------------------------

Deaths due to infection were almost 2-fold increased in patients suffering from severe vitamin D deficiency (adjusted HR: 1.92, 95% CI: 0.82--4.51). Per unit decrease in log transformed 25(OH)D, the rate of fatal infections rose by 46% (adjusted HR: 1.46, 95% CI: 0.96--2.23). Furthermore, deaths due to all causes increased significantly by 39% per unit decrease in log 25(OH)D. Patients with levels \<25 nmol/L had an adjusted 79% higher risk of death as compared with patients with sufficient 25(OH)D levels (*Tables [2](#EHQ246TB2){ref-type="table"}* and *[3](#EHQ246TB3){ref-type="table"}*).

There were no significant interactions of statin use, active vitamin D treatment as well as prior CVD in our prospective analyses indicating that the association of 25(OH)D levels with event rates is not different in patients with and without statin or active vitamin D treatment as well as prior CVD.

Linearity assumptions for all Cox regression analyses were evaluated by log-minus-log survival plots and partial (Schönfeld) residuals vs. survival time plots and found valid.

Discussion {#s4}
==========

We have shown that vitamin D deficiency is an independent risk factor for SCD, CVE, and all-cause mortality in diabetic haemodialysis patients. These associations were independent of common known risk factors. There were also borderline non-significant associations of severe vitamin D deficiency with increased risk of stroke and fatal infections.

Our study is the first to highlight the role of vitamin D deficiency as a risk factor of adverse long-term outcomes in diabetic haemodialysis patients. Strengths of our study are the large sample size, the well-characterized cohort of diabetic haemodialysis patients, and the detailed long-term follow-up. Our data are in line with observations in other cohorts of CKD patients,^[@EHQ246C2]--[@EHQ246C7]^ inpatients referred for coronary angiography,^[@EHQ246C12],[@EHQ246C13]^ as well as in population-based cohorts.^[@EHQ246C15]--[@EHQ246C18]^ These latter studies showed an increased risk of mortality and/or CVE in individuals with low 25(OH)D levels.^[@EHQ246C2]--[@EHQ246C7],[@EHQ246C12],[@EHQ246C13],[@EHQ246C15]--[@EHQ246C18]^ Previous observations on specifically strong associations of vitamin D deficiency with MI and heart failure could, however, not be clearly confirmed in the 4D study.^[@EHQ246C12],[@EHQ246C16]^ Given that most haemodialysis patients are vitamin D deficient, we believe that our findings might have significant clinical implications when considering that natural vitamin D supplementation is considered a relatively safe, easy, and cheap therapy.^[@EHQ246C19]^ We are aware of a history of promising data on risk factors of mortality in haemodialysis patients leading to the initiation of RCTs, which failed to show significant effects of targeted treatments.^[@EHQ246C20]^ Without claiming causality for our findings, we want to stress that vitamin D exerts various effects that might, in a causal manner, underlie harmful consequences of vitamin D deficiency.^[@EHQ246C10]^

First, we want to point out that classic effects of vitamin D related to calcium and phosphorus homoeostasis as well as PTH regulation might of course play an important role for cardiovascular risk in CKD.^[@EHQ246C21]^ Reduced vitamin D metabolites lead to hypocalcaemia and secondary hyperparathyroidism, which is associated with increased mortality risk.^[@EHQ246C22]--[@EHQ246C24]^ In this context, previous studies indicate that natural vitamin D or 25(OH)D supplementation might have beneficial effects on mineral metabolism including reductions in PTH levels.^[@EHQ246C22],[@EHQ246C25]^ Results on this latter topic are, however, inconsistent and further studies are required.^[@EHQ246C22],[@EHQ246C25]^ Interestingly, our prospective results did not materially change even after adjustments for various parameters of mineral metabolism suggesting that other mechanisms might have mainly driven the association of low 25(OH)D and adverse outcomes in the 4D study. Associations of vitamin D deficiency with cardiovascular risk factors including type 2 diabetes mellitus,^[@EHQ246C26]^ arterial hypertension,^[@EHQ246C27]^ malnutrition, and inflammation may hypothetically explain the increased mortality risk in patients with low 25(OH)D levels. Adjustments for these latter risk factors had, however, only little impact on our prospective analyses. Hence, other mechanisms may be relevant. Data from the Multi-Ethnic Study of Atherosclerosis suggest that vitamin D deficiency is prospectively associated with increased risk of coronary artery calcification.^[@EHQ246C28]^ This relationship seemed to be stronger for patients with lower estimated glomerular filtration rate, and there was no significant association of 1,25(OH)2D and coronary artery calcification.^[@EHQ246C28]^ This latter result does not necessarily argue against important vascular protective actions of 1,25(OH)2D because circulating levels of 1,25(OH)2D are not necessarily correlated with its tissue levels. Previous study results suggest direct anti-atherosclerotic effects on endothelial and vascular smooth muscle cells as well as on macrophages whose foam cell formation was inhibited by 1,25(OH)2D.^[@EHQ246C29],[@EHQ246C30]^ The strong association of vitamin D deficiency with SCD but not with MI might, however, suggest that atherosclerosis related to vitamin D deficiency might not be the main pathophysiological link for our findings. Direct vitamin D effects on the myocardium, which expresses the vitamin D receptor (VDR) as well as 1α-hydroxylase,^[@EHQ246C31],[@EHQ246C32]^ may, therefore, be of importance. Experimental animal studies revealed myocardial hypertrophy and dysfunction with a hypercontractile state in both conditions of vitamin D deficiency as well as in VDR knockout models,^[@EHQ246C10],[@EHQ246C33],[@EHQ246C34]^ even if VDR knockout was exclusively performed in cardiomyocytes.^[@EHQ246C35]^ Clinical studies confirmed the associations of vitamin D deficiency with CHF and in particular with diastolic dysfunction but our results regarding heart failure deaths, which are limited by relatively low numbers of events, do not support an important role of vitamin D in this context.^[@EHQ246C31],[@EHQ246C36],[@EHQ246C37]^ Furthermore, altered myocardial calcium flux and increased risk of SCD related to a poor vitamin D status suggest a link to cardiac arrhythmias.^[@EHQ246C12],[@EHQ246C31],[@EHQ246C38]^ This notion is in line with observations in haemodialysis patients showing that calcitriol reduced a prolonged QT interval, which is a risk factor for SCD, the single largest cause of death in dialysis patients.^[@EHQ246C39],[@EHQ246C40]^ Apart from this, detrimental consequences of vitamin D deficiency might also be mediated by an increased risk of infections, which is supported by our data showing a borderline non-significant association of vitamin D deficiency with fatal infections.^[@EHQ246C41]^ In line with previous data, we also found a non-significant association of low 25(OH)D levels with increased risk of strokes.^[@EHQ246C13]^ With reference to strokes, vitamin D might not only be useful for the prevention but also for the treatment when considering its neuromuscular and osteoprotective effects.^[@EHQ246C8]--[@EHQ246C10]^

Our data should be viewed in light of a meta-analysis, which showed significantly improved survival of natural vitamin D supplementation in individuals without end-stage renal failure.^[@EHQ246C42]^ We are aware that findings from RCTs among patients free of advanced CKD cannot be uncritically extrapolated to haemodialysis patients.^[@EHQ246C20],[@EHQ246C22]^ We also want to underline that physicians, impressed by previous data in favour of multiple health benefits of natural vitamin D and by the magnitude of the present observed associations should not abstain from future RCTs, which are urgently needed. Unless these trial results are published, our vitamin D prescription among haemodialysis patients should be guided by considerations that weight the probable benefit vs. the probable risks and costs of this therapy. Supplementation of natural vitamin D to reach proposed optimal 25(OH)D levels of 75--150 nmol/L is considered safe (intoxication starts at \>500 nmol/L),^[@EHQ246C43]^ and it should be kept in mind that sunbathing can produce up to 20 000 IU vitamin D per day.^[@EHQ246C8],[@EHQ246C9],[@EHQ246C19]^ This latter dose is much higher than required to reach 25(OH)D target levels by using the rule of thumb that 1000 IU vitamin D can increase 25(OH)D levels by ∼25 nmol/L in patients without severe CKD.^[@EHQ246C8],[@EHQ246C9],[@EHQ246C19]^

It should, however, also be pointed out that reversed causation might be mainly responsible for our prospective results. Hence, we cannot rule out that vitamin D deficiency is simply a consequence of a poor health status and not the cause of an adverse health outcome. In this context, it should be mentioned that our data are limited due to the observational nature of our study, which precludes any conclusion regarding cause and effect relationships of our results. Despite the extensive adjustments, we cannot exclude residual confounding. A further limitation of our work is that due to lack of data we were not able to study interactions and confounding by levels of 1,25(OH)2D or fibroblast growth factor-23, which suppresses 1,25(OH)2D synthesis.^[@EHQ246C44]^ Associations of 25(OH)D and outcome measures were, however, independent of parameters of mineral metabolism and the use of active vitamin D treatment. Another drawback of our work is missing data on left ventricular ejection fraction and severity of CAD.

In conclusion, we observed that low 25(OH)D levels are associated with increased risks of SCD, CVE, and mortality, and there was, furthermore, a borderline non-significant association of vitamin D deficiency with increased risk of strokes and fatal infections. The magnitude of the observed associations, as well as previous data in favour of multiple health benefits of natural vitamin D, point to the urgent need for an RCT. Such study can clarify whether the relatively easy, safe, and cheap supplementation therapy with vitamin D can decrease adverse outcomes, in particular SCD, in haemodialysis patients.
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[^5]: ^b^Model 2: additionally adjusted for levels of parathyroid hormone, calcium, and phosphate.

[^6]: ^a^Model 1: adjusted for age, sex, atorvastatin treatment, season, coronary artery disease, congestive heart failure, systolic blood pressure, smoking, duration of dialysis, ultrafiltration volume, body mass index, levels of LDL-, HDL-cholesterol, C-reactive protein, HbA1c, use of beta-blockers, ACE inhibitors, and diuretics.

[^7]: ^b^Model 2: additional adjustments for PTH, calcium, and phosphate.
